ArticleThe Journal of clinical investigation2011
Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity.
Article in The Journal of clinical investigation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 48 citations in OpenAlex.
- IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.The Journal of clinical investigation · 2012Trial
- Beyond α-GalCer: Medicinal Chemistry Insights Driving Structural Evolution of CD1d Ligands.Journal of medicinal chemistry · 2026Review
- Innate-like T Cell Biology in the Tumor Microenvironment Implications for Cancer Immunotherapy.Cells · 2026Review
- A structural perspective of how T cell receptors recognize the CD1 family of lipid antigen-presenting molecules.The Journal of biological chemistry · 2024Review
- Lysosomal processing of sulfatide analogs alters target NKT cell specificity and immune responses in cancer.The Journal of clinical investigation · 2023Article
- The role of NKT cells in gastrointestinal cancers.Oncoimmunology · 2022Review
- CD138 expression is a molecular signature but not a developmental requirement for RORγt+ NKT17 cells.JCI insight · 2021Article
- Synthetic preparation and immunological evaluation of β-mannosylceramide and related N-acyl analogues.Organic & biomolecular chemistry · 2020Article
- Complementary approaches to study NKT cells in cancer.Methods in enzymology · 2020Article
- Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies.Frontiers in immunology · 2020Review
- Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d.Frontiers in immunology · 2019Article
- Tissue-Specific Roles of NKT Cells in Tumor Immunity.Frontiers in immunology · 2018Review
- The Role of Natural Killer T Cells in Cancer-A Phenotypical and Functional Approach.Frontiers in immunology · 2018Review
- The Yin and Yang of Invariant Natural Killer T Cells in Tumor Immunity-Suppression of Tumor Immunity in the Intestine.Frontiers in immunology · 2017Review
- Immunotherapeutic strategies targeting natural killer T cell responses in cancer.Immunogenetics · 2016Review
- Non-glycosidic compounds can stimulate both human and mouse iNKT cells.European journal of immunology · 2016Article
- Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression.Bone marrow transplantation · 2016Review
- Antigen specificity of invariant natural killer T-cells.Biomedical journal · 2015Review
- Synthesis of a 2"-deoxy-β-GalCer.Molecules (Basel, Switzerland) · 2014Article
- The immunoregulatory role of type I and type II NKT cells in cancer and other diseases.Cancer immunology, immunotherapy : CII · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 3 countries.
Funding
Abstract
Type 1 or invariant NKT (iNKT) cell agonists, epitomized by α-galactosylceramide, protect against cancer largely by IFN-γ-dependent mechanisms. Here we describe what we believe to be a novel IFN-γ-independent mechanism induced by β-mannosylceramide, which also defines a potentially new class of iNKT cell agonist, with an unusual β-linked sugar. Like α-galactosylceramide, β-mannosylceramide directly activates iNKT cells from both mice and humans. In contrast to α-galactosylceramide, protection by β-mannosylceramide was completely dependent on NOS and TNF-α, neither of which was required to achieve protection with α-galactosylceramide. Moreover, at doses too low for either alone to protect, β-mannosylceramide synergized with α-galactosylceramide to protect mice against tumors. These results suggest that treatment with β-mannosylceramide provides a distinct mechanism of tumor protection that may allow efficacy where other agonists have failed. Furthermore, the ability of β-mannosylceramide to synergize with α-galactosylceramide suggests treatment with this class of iNKT agonist may provide protection against tumors in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.